Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Preclinical evaluation of a CXCR4-specific (68)Ga-labelled TN14003 derivative for cancer PET imaging.

George GP, Stevens E, Åberg O, Nguyen QD, Pisaneschi F, Spivey AC, Aboagye EO.

Bioorg Med Chem. 2014 Jan 15;22(2):796-803. doi: 10.1016/j.bmc.2013.12.012. Epub 2013 Dec 11.

PMID:
24365390
2.

Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression.

Hennrich U, Seyler L, Schäfer M, Bauder-Wüst U, Eisenhut M, Semmler W, Bäuerle T.

Bioorg Med Chem. 2012 Feb 15;20(4):1502-10. doi: 10.1016/j.bmc.2011.12.052. Epub 2012 Jan 2.

PMID:
22264762
3.

PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.

Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ.

J Nucl Med. 2011 Nov;52(11):1803-10. doi: 10.2967/jnumed.111.098798.

4.

In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366.

D'Alessandria C, Pohle K, Rechenmacher F, Neubauer S, Notni J, Wester HJ, Schwaiger M, Kessler H, Beer AJ.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):953-63. doi: 10.1007/s00259-015-3218-z. Epub 2015 Oct 24.

PMID:
26497698
5.

Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.

Hartimath SV, van Waarde A, Dierckx RA, de Vries EF.

Mol Pharm. 2014 Nov 3;11(11):3810-7. doi: 10.1021/mp500398r. Epub 2014 Aug 18.

PMID:
25094028
6.

Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.

Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, Wester HJ, Kropf S, Lapa C, Schirbel A, Buck AK, Herrmann K.

Clin Nucl Med. 2017 Jan;42(1):e29-e34.

PMID:
27819856
7.

A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging.

Sano K, Masuda R, Hisada H, Oishi S, Shimokawa K, Ono M, Fujii N, Saji H, Mukai T.

Bioorg Med Chem Lett. 2014 Mar 1;24(5):1386-8. doi: 10.1016/j.bmcl.2014.01.031. Epub 2014 Jan 21.

PMID:
24491461
8.

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Šimeček J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M.

Theranostics. 2015 Mar 1;5(6):618-30. doi: 10.7150/thno.11251. eCollection 2015.

9.

Improvement of CXCR4 tracer specificity for PET imaging.

Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, Peled A, Eden HS, Farber JM, Chen X.

J Control Release. 2012 Jan 30;157(2):216-23. doi: 10.1016/j.jconrel.2011.09.076. Epub 2011 Sep 22.

10.

PET of tumor CXCR4 expression with 4-18F-T140.

Jacobson O, Weiss ID, Kiesewetter DO, Farber JM, Chen X.

J Nucl Med. 2010 Nov;51(11):1796-804. doi: 10.2967/jnumed.110.079418. Epub 2010 Oct 18.

11.

[⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.

Hartimath SV, Domanska UM, Walenkamp AM, Rudi A J O D, de Vries EF.

Nucl Med Biol. 2013 May;40(4):507-17. doi: 10.1016/j.nucmedbio.2013.02.003. Epub 2013 Mar 20.

12.

Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).

Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, G Lesniak W, Mease RC, Pomper MG, Nimmagadda S.

Nucl Med Biol. 2014 Aug;41(7):552-61. doi: 10.1016/j.nucmedbio.2014.04.081. Epub 2014 Apr 21.

13.

In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.

Fani M, Tamma ML, Nicolas GP, Lasri E, Medina C, Raynal I, Port M, Weber WA, Maecke HR.

Mol Pharm. 2012 May 7;9(5):1136-45. doi: 10.1021/mp200418f. Epub 2012 Apr 23.

PMID:
22497506
14.

A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.

Pan D, Xu YP, Yang RH, Wang L, Chen F, Luo S, Yang M, Yan Y.

Amino Acids. 2014 Jun;46(6):1481-9. doi: 10.1007/s00726-014-1718-y. Epub 2014 Mar 17.

PMID:
24633452
15.

AMD3100: A Versatile Platform for CXCR4 Targeting (68)Ga-Based Radiopharmaceuticals.

Poty S, Gourni E, Désogère P, Boschetti F, Goze C, Maecke HR, Denat F.

Bioconjug Chem. 2016 Mar 16;27(3):752-61. doi: 10.1021/acs.bioconjchem.5b00689. Epub 2016 Mar 3.

PMID:
26886512
16.

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.

Lapa C, Lückerath K, Kleinlein I, Monoranu CM, Linsenmann T, Kessler AF, Rudelius M, Kropf S, Buck AK, Ernestus RI, Wester HJ, Löhr M, Herrmann K.

Theranostics. 2016 Jan 25;6(3):428-34. doi: 10.7150/thno.13986. eCollection 2016.

17.

Positron emission tomographic imaging of CXCR4 in cancer: challenges and promises.

George GP, Pisaneschi F, Nguyen QD, Aboagye EO.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00041. Review.

PMID:
25341373
18.

PET imaging of CXCR4 receptors in cancer by a new optimized ligand.

Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ.

ChemMedChem. 2011 Oct 4;6(10):1789-91. doi: 10.1002/cmdc.201100320. Epub 2011 Jul 20. No abstract available.

19.

Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.

Selvaraju RK, Velikyan I, Asplund V, Johansson L, Wu Z, Todorov I, Shively J, Kandeel F, Eriksson B, Korsgren O, Eriksson O.

Nucl Med Biol. 2014 Jul;41(6):471-6. doi: 10.1016/j.nucmedbio.2014.03.017. Epub 2014 Mar 29.

PMID:
24857864
20.

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.

Tolmachev V, Velikyan I, Sandström M, Orlova A.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1356-67. doi: 10.1007/s00259-009-1367-7. Epub 2010 Feb 4.

PMID:
20130858

Supplemental Content

Support Center